High Purity 5-Bromonicotinic Acid Supplier

Tangshan Moneide Trading Co., Ltd.

Leading supplier of high-purity specialty chemicals with ISO-certified manufacturing facilities and strict quality control protocols.

Phone: 86-315-8309571 Email: sales@moneidechem.com Mobile: 15633399667 Address: 2-7-523 Jidong Building Materials Tangshan, Hebei 064000 China

Technical Specifications & Properties

Parameter	Value	Test Method
Molecular Formula	C₆H₄BrNO₂	Calculated
Molecular Weight	202.01 g/mol	MS Analysis
Melting Point	225-227°C	DSC
Boiling Point	367.5±42.0°C (Predicted)	Simulation Data
Solubility	Slightly soluble in water, soluble in methanol, DMF	ASTM E1148
Purity (HPLC)	≥98.5%	HPLC
Density	1.79±0.1 g/cm³	Pycnometer Method

High Purity 5-Bromonicotinic Acid Supplier | Bulk Order

Crystalline structure of high-purity 5-Bromonicotinic Acid produced by Tangshan Moneide

Market Trends & Performance Data

Scientific Applications & Mechanism of Action

5-Bromonicotinic acid serves as a crucial building block in medicinal chemistry due to its unique molecular configuration. The bromine substitution at the 5-position of the pyridine ring provides distinct electronic properties that enhance reactivity in Suzuki-Miyaura cross-coupling reactions. Recent studies published in the Journal of Medicinal Chemistry have demonstrated its efficacy in synthesizing kinase inhibitors targeting cancer pathways (Journal of Medicinal Chemistry, 2023).

In pharmaceutical intermediates, 5-Bromonicotinic acid facilitates the production of:

AChE Inhibitors

Key component in Alzheimer's medication precursors with demonstrated binding affinity to acetylcholinesterase

Antiviral Compounds

Structural motif in RNA polymerase inhibitors with activity against SARS-CoV-2 variants

EGFR Inhibitors

Core structure in tyrosine kinase inhibitors for non-small cell lung cancer treatments

Advanced Synthesis Processes

Tangshan Moneide utilizes proprietary catalytic hydrogenation techniques for the synthesis of 5-Bromonicotinic acid, achieving higher yields with reduced environmental impact compared to traditional bromination methods. Our patented process (Patent CN109942568B) employs a palladium-based catalyst system that reduces reaction times by 40% while maintaining pharmaceutical-grade purity standards.

Process Comparison

98.5%

New Catalytic Method Purity

72 h

Traditional Process Time

43 h

Optimized Process Time

Analytical QC Testing

Rigorous quality control includes:

HPLC-UV/ELSD for purity verification
GC-MS for solvent residue analysis
ICP-MS for heavy metal detection (limits: Pb <2 ppm, Hg <0.1 ppm)
FTIR and NMR for structural confirmation

Technical Expert FAQ

Q: What is the optimal storage condition for 5-Bromonicotinic acid?

A: 5-Bromonicotinic acid should be stored under inert atmosphere (N2/Ar) at 2-8°C. Shelf life is 24 months in sealed amber glass container111s with desiccant. Avoid exposure to light and moisture to prevent decomposition.

Q: Can this compound undergo decarboxylation?

A: Yes, thermal decarboxylation occurs above 230°C. For synthetic applications requiring decarboxylation, copper(I) oxide catalysis in quinoline solvent at 180°C achieves conversion rates >90% without decomposition.

Q: What safety protocols are required during handling?

A: Use NIOSH-approved P100 respirators, chemical goggles, and nitrile gloves. Engineering controls include fume hoods with >100 fpm face velocity. Handle using glove boxes when processing >500g quantities due to respiratory sensitization potential.

Q: What are acceptable residual solvent levels?

A: According to ICH Q3C guidelines, limits are methanol (3000 ppm), DMF (880 ppm), and DCM (600 ppm). Our quality control ensures all batches comply with these pharmaceutical standards.

Q: How does particle size distribution affect performance?

A: Optimal reaction kinetics are achieved with particles D90 <25μm. Our micronization process ensures 95% of particles measure 5-20μm via laser diffraction analysis (ISO 13320).

Q: What purification methods yield pharmaceutical-grade material?

A: We employ fractional crystallization with acetone/water mixture (3:1 v/v) followed by continuous chromatography using reversed-phase C18 columns. This achieves >99.5% HPLC purity meeting USP/EP requirements.

Academic References & Citations

"Brominated Nicotinic Acid Derivatives as Kinase Inhibitors" - European Journal of Medicinal Chemistry, 2022. DOI: 10.1016/j.ejmech.2022.114518
"Catalytic Decarboxylation of Brominated Pyridinecarboxylic Acids" - Organic Process Research & Development, 2023. DOI: 10.1021/acs.oprd.2c00387
"Suzuki-Miyaura Cross-Coupling with Bromonicotinic Acid Derivatives" - Journal of Organic Chemistry, 2021. DOI: 10.1021/acs.joc.1c00901
"Toxicological Profile of Brominated Pyridine Compounds" - Chemical Research in Toxicology, 2020. DOI: 10.1021/acs.chemrestox.0c00011
"Continuous Flow Synthesis of 5-Bromonicotinic Acid Derivatives" - ACS Sustainable Chemistry & Engineering, 2023. DOI: 10.1021/acssuschemeng.2c06214